Inclusion Criteria:

- At least 18 years of age

- Histologically confirmed diagnosis of urothelial carcinoma of the bladder, urethra,
ureter, or renal pelvis

- Measurable disease (revised RECIST; Version 1.1)

- Karnofsky performance status ≥ 60%

- Previously treated with not more than 1 doublet or triplet regimen and that regimen
contained gemcitabine and a platinum agent

- Adequate bone marrow, hepatic, and renal function, as specified in the protocol

- At least 4 weeks and recovery from effects of prior surgery, prior radiotherapy, or
other therapy with an approved or investigational agent

- Ability to swallow an oral solid-dosage form of medication

Exclusion Criteria:

- Known metastasis or symptoms of metastasis to the central nervous system

- Significant medical disease other than cancer

- Presence of neuropathy > Grade 1 (NCI CTC, Version 4.0)

- Prior treatment with a taxane or other tubulin-targeted agent (eg, indibulin) other
than a vinca alkaloid

- Need to continue any regularly-taken medication that is a potent inhibitor or inducer
of the CYP3A pathway or P-glycoprotein activity